Reading NRXS? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track NRXS free→Reading NRXS? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track NRXS free→AMEXHealth CareBiotechnologySnapshot 2026-06-16
Recent financial performance sits below its industry cohort — worth keeping an eye on, though it has not freshly broken.
Recent financial performance is neutral, and earnings quality cannot be assessed as the company was unprofitable over the past year. Management's recent track record has been fairly steady, while risk is high and the sector backdrop is a headwind. Peer multiples imply a price about 44% below where it trades (it looks expensive on this basis), and the read is rich, as it trades above peer multiples without sufficient growth to justify that valuation. Key factors to watch include any guidance cuts from NRXS and the performance of sector bellwethers like VRTX, REGN, and ARGX. This read is provisional.
Daily closes. Earnings/event dots are placed inline.
A consensus fair price across 2 valuation methods, at three horizons. Current price $6.72. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
No-growth: today's peer multiple on trailing earnings. The headline read.
Embeds projected growth. Leans optimistic by design. Upside context.
We take the 12-month fair value above and grade our own number — how the market prices this name versus what we'd justify, and where the two diverge.
At $6.82 NRXS trades at 12× p/s — 1.3× the 9× p/s peer median. The market is re-rating it beyond its own range; our $6.81 fair value is medium-confidence here. Not investment advice.
One valuation read at a 12-month horizon, plus how price compares to peers and the company's own history.
The market is pricing in roughly 0% of near-term growth above a flat-multiple fair value; not enough history to forecast a comparison. This describes what's priced in, not a forecast of the move.
TTM earnings are negative, so the read leans on sales- and cash-flow-based methods rather than P/E. This is a data condition, not a forward call.
Only a turbulent sector regime (Heating) — not the full expensive x weak x turbulent stack.
For similar setups historically (n=20,154): about 33% saw a 20%+ drawdown, and roughly 76% of those did not recover within the year. These are historical base rates for the cohort, not a forecast of this stock.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 1 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated neutral grew net income 50% of the time over the next year (vs 57% for the rest of the cohort, n=3115).
Over the trailing year it converted 0.83x of net income into operating cash flow.
Not enough signal yet.
Not enough signal to read sensitivity to the broad stock market, the US dollar, Fed net liquidity, real (inflation-adjusted) rates, long-term interest rates.
9 material management or governance events in the past 24 months, led by capital-allocation actions. Historically, Health Care names rated neutral grew net income 58% of the time over the next year (vs 50% for the rest of the cohort, n=842).
The next print and the backdrop around it (sector regime and the AI cycle). Context for the path, not a forecast of returns.
EPS estimate $-0.17 → $-0.32 (-93.9% / 30d). 0 raised, 1 cut, 2 covering analysts.
0 upgrades, 0 downgrades / 30d. 100% of analysts rate Buy.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
What a normal day, a bad day, and the worst of the last year would mean for a $10,000 position.
On a typical day, $10k can swing ±$279.
How much price usually moves either way.
On a bad day, this stock has moved -$635.
A rough but not unusual down day (about the 95th percentile).
In the worst 12 months, $10k could have lost $3,953.
Deepest peak-to-trough drop in the last year.
Past results, not a forecast. Not investment advice.
The most important moves since the prior daily snapshot.
Valuation label changed from 'expensive' to 'fair'.
As of June 15, 2026, the valuation changed, moving to an expensive label. Risk remained high, and the sector backdrop was noted as a headwind. The company is still categorized as loss-making in terms of earnings quality. The overall context suggests that the stock trades above peer multiples, indicating a rich valuation setup.
as of 2026-06-16
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
No named catalysts to watch right now. Check back after the next earnings report.
Recent news graded against this company's own objectives — whether it reinforces or challenges the thesis, and how confirmed it is.
No graded news catalysts for NRXS yet.
Conditional scenarios: if X happens, the view would shift in this direction. These are not predictions.
No upside scenarios in the latest snapshot.
No downside scenarios in the latest snapshot.
Recent SEC 8-K filings ranked by likely impact, confidence, and recency.
Results of Operations and Financial Condition On April 21, 2026, Neuraxis, Inc. (the “Company”), issued disclosure that, on a preliminary unaudited basis, the Company expects its cash and cash equivalents to be approximately $7.1 million as of March 31, 2026. The Company expects its net sales to be approximately $1.6 million for the three months ended March 31, 2026, as compared to approximately $0.9 million for the three months ended March 31, 2025. On a preliminary unaudited basis, the Comp…
Whether the overall read has been drifting up or down lately, and how it's changed since last week.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Long-thesis check; widest uncertainty.
TTM earnings are negative. P/E-based methods drop out and the estimate leans on sales- and cash-flow-based methods. A data condition, not a forward call.
Looks more expensive than peers.
Self-history needs ~20 months of data.
Trailing four: 2025-Q1, 2025-Q2, 2025-Q3, 2026-Q1
A side-by-side read on sector standing, valuation, and risk versus Biotechnology.
| Stock | Sector standing | Valuation | Risk |
|---|---|---|---|
NRXS Neuraxis Inc | Above typical Show detailsSector percentile: 88 of 100 | fair | high |
ABBV AbbVie | Above typical Show detailsSector percentile: 85 of 100 | fair | low |
AMGN Amgen | Above typical Show detailsSector percentile: 77 of 100 | full | moderate |
GILD Gilead Sciences | Above typical Show detailsSector percentile: 100 of 100 | fair | moderate |
VRTX Vertex Pharmaceuticals | Above typical Show detailsSector percentile: 79 of 100 | expensive | moderate |
Not investment advice. As of 2026-06-16.
via XLV
Tailwind = sector leading the S&P 500; headwind = trailing. Both can be constructive. Historically, headwind regimes have averaged stronger forward returns than tailwind.
Context label only: describes the market state (e.g. real bear vs narrative panic, healthy uptrend vs late-stage froth). It is not a per-ticker buy/sell signal and does not predict factor performance.
Not investment advice. As of 2026-06-16.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Focus on increasing revenue, as evidenced by recent earnings beat and guidance.
Stated in 2 of last 2 quarters. Revenue grew from $968,127 in 2025-Q4 to $1,607,883 in 2026-Q1, indicating a positive trajectory. The company has consistently focused on revenue growth, as evidenced by the earnings beat and guidance.
“The Company expects its net sales to be approximately $1.6 million for Q1 2026.”
“Revenue was $968,127, showing growth from previous quarters.”
Address ongoing operating losses to improve financial health.
Stated in 3 of last 3 quarters. Operating income improved from -$2,100,085 in 2025-Q3 to -$1,740,679 in 2026-Q1, showing limited progress in reducing losses. Management continues to focus on addressing these losses.
“Operating income was -$1,740,679 in Q1 2026.”
“Operating income was -$1,716,867 in Q4 2025.”
Ensure sufficient cash reserves to support operations and strategic initiatives.
Newly stated in 2026-Q1. The company expects its cash and cash equivalents to be approximately $7.1 million as of March 31, 2026. This indicates a focus on maintaining sufficient cash reserves to support operations and strategic initiatives.
Other Events. As previously disclosed, on August 29, 2025, the Company entered into an At The Market Offering Agreement (the “Agreement”) with Craig-Hallum Capital Group LLC (the “Sales Agent”) under which the Company may offer and sell, from time to time at its sole discretion, shares of its $0.001 par value common stock (the “Common Stock”), having an aggregate offering price of up to $6,270,000, through the Sales Agent as its sales agent. Pursuant to the Agreement, sales of the Common Stoc…
Results of Operations and Financial Condition On October 23, 2025, Neuraxis, Inc. (the “Company”), issued disclosure that, on a preliminary unaudited basis, the Company expects its cash and cash equivalents to be approximately $4.4 million as of September 30, 2025. On a preliminary unaudited basis, the Company expects its net sales to be approximately $0.8 million, its gross profits to be approximately $0.7 million, and its operating loss to be approximately $2.1 million, for the three months…
Other Events. FDA 510(k) Clearance NeurAxis, Inc. (“NeurAxis” or the “Company”) today announced that it has received U.S. Food and Drug Administration (the “FDA”) 510(k) clearance for its proprietary percutaneous electrical nerve field stimulation (“PENFS”) technology for the treatment of functional abdominal pain (“FAP”) associated with functional dyspepsia (“FD”), and FD related nausea symptoms, in patients aged 8 years and older. The FDA reviewed the clinical literature supporting the use…
Entry into a Material Definitive Agreement. On August 29, 2025, Neuraxis, Inc. (the “ Company ”) entered into an At The Market Offering Agreement (the “ Agreement ”) with Craig-Hallum Capital Group LLC (the “ Sales Agent ”) under which the Company may offer and sell, from time to time at its sole discretion, shares of its $0.001 par value common stock (the “ Common Stock ”), having an aggregate offering price of up to $3,300,000, through the Sales Agent as its sales agent. Pursuant to the Agr…
“Operating income was -$2,100,085 in Q3 2025.”
“The Company expects its cash and cash equivalents to be approximately $7.1 million as of March 31, 2026.”